Biological variation in tests of hemostasis

Seminars in Thrombosis and Hemostasis

Volumn 34, Issue 7, 2008, Pages 635-641

  Banfi, Giuseppe ^a,b   Del Fabbro, Massimo ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b IRCCS ISTITUTO ORTOPEDICO GALEAZZI   (Italy)

Author keywords

Biological variation; Coagulation tests; Critical difference; Individuality index

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; FIBRINOGEN; FIBRINOPEPTIDE A; PLASMINOGEN ACTIVATOR INHIBITOR 1; VON WILLEBRAND FACTOR;

AGE DISTRIBUTION; BIODIVERSITY; BODY MASS; CIRCADIAN RHYTHM; HEMOSTASIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; MEDICAL RESEARCH; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; REVIEW; SCREENING TEST; SEX DIFFERENCE;

AGE FACTORS; ANTITHROMBIN III; BODY MASS INDEX; CIRCADIAN RHYTHM; FIBRINOGEN; FIBRINOPEPTIDE A; HEMOSTASIS; HUMANS; OBSERVER VARIATION; PARTIAL THROMBOPLASTIN TIME; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN TIME; SEX FACTORS; THROMBIN TIME;

EID: 58149092857     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0028-1104541     Document Type: Review

References (44)

1. Fraser CG. Inherent biological variation and reference values. Clin Chem Lab Med 2004;42:758-764
2. Fraser CG, Wilkinson SP, Neville RG, et al. Biologic variation of common hematologic quantities in the elderly. Am J Clin Pathol 1989;92:465-470
3. Sebastian-Gambaro MA, Lirón-Hernández J, Fuentes-Arderiu X. Intra- and inter-individual biological variability data bank. Eur J Clin Chem Clin Biochem 1997;35:845-852
4. Dot D, Mirò J, Fuentes-Arderiu X. Within-subject biological variation of prothrombin time and activated partial thromboplastin time. Ann Clin Biochem 1992;29:422-425
5. Costongs GMPJ, Janson PCW, Bas BM, Hermans J, Brombacher PJ, van Wersch JWJ. Short-term and long-term intraindividual variations and critical differences of haematological laboratory parameters. J Clin Chem Clin Biochem 1985;23:69-76
6. Costongs GMPJ, Bas BM, Janson PCW, et al. Short-term and long-term intraindividual variations and critical differences of coagulation parameters. J Clin Chem Clin Biochem 1985;23:405-410
7. Wada Y, Kutihara M, Toyofuku M, et al. Analytical goals for coagulation tests based on biological variation. Clin Chem Lab Med 2004;42:79-83
8. Ricos C, Alvarez V, Cava F, et al. Current databases on biological variation: pros, cons and progress. Scand J Clin Lab Invest 1999;59:491-500
9. Kouri T, Siloaho M, Pohjavaara S, et al. Pre-analytical factors and measurement uncertainty. Scand J Clin Lab Invest 2005;65:463-475
10. Lassen JF, Branslund I, Antonsen S. International normalized ratio for prothrombin times in patients taking oral anticoagulants: critical difference and probability of significant change in consecutive measurements. Clin Chem 1995;41:444-447
11. Lippi G, Franchini M, Guidi GC. Diagnostic approach to inherited bleeding disorders. Clin Chem Lab Med 2007;45:2-12
12. Sakkinen PA, Macy EM, Callas PW, et al. Analytical and biologic variability in measures of hemostasis, fibrinolysis, and inflammation: assessment and implications for epidemiology. Am J Epidemiol 1999;149:261-267
13. de Maat MP, de Bart AC, Hennis BC, et al. Interindividual and intraindividual variability in plasma fibrinogen, TPA antigen, PAI activity, and CRP in healthy, young volunteers and patients with angina pectoris. Arterioscler Thromb Vasc Biol 1996;16:1156-1162
14. Maes M, Scharpé S, Cooreman W, et al. Components of biological, including seasonal, variation in haematological measurements and plasma fibrinogen concentrations in normal humans. Experientia 1995;51:141-149
15. Väisänen S, Rauramaa R, Penttilä I, et al. Variation in plasma fibrinogen over one year: relationships with genetic polymorphisms and non-genetic factors. Thromb Haemost 1997;77:884-889
16. De Lange M, de Geus EJC, Kluft C, et al. Genetic influences on fibrinogen, tissue plasminogen activator-antigen and von Willebrand factor in males and females. Thromb Haemost 2006;95:414-419
17. Chambless LE, McMahon RP, Brown SA, Patsch W, Heiss G, Shen Y. Short-term intraindividuality variability in lipoprotein measurements: the atherosclerosis risk in communities study. Am J Epidemiol 1992;136:1069-1081
18. Salomaa V, Rasi V, Stenga° rd J, et al. Intra- and interindividual variability of hemostatic factors and traditional cardiovascular risk factors in a three-year follow-up. Thromb Haemost 1998;79:969-974
19. The Fibrinogen Studies Collaboration. Associations of plasma fibrinogen levels with established cardiovascular disease risk factors, inflammatory markers, and other characteristics: individual participant meta-analysis of 154,211 adults in 31 prospective studies. Am J Epidemiol 2007;166:867-879
20. Bolon-Larger M, Chamouard V, Bressolle F, Boulieu R. A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation of coagulation factor VIII in patients with hemophilia A. Ther Drug Monit 2007;29:20-26
21. Horne MK, McCloskey DJ, Cullinane AM, et al. Parameters of coagulant and fibrinolytic capacity and activity in postmenopausal women: within-subject variability. Thromb Res 2002;107:229-233
22. Nguyen ND, Ghaddar H, Stinson V, Chambless LE, Wu KK. ARIC hemostasis study - IV. Intraindividual variability and reliability of hemostatic factors. Thromb Haemost 1995;73:256-260
23. Marckmann P, Sandström B, Jespersen J. The variability of and association between measures of blood coagulation, fibrinolysis and blood lipids. Atherosclerosis 1992;96:235-244
24. Thompson SG, Martin JC, Meade TW. Sources of variability in coagulation factor assays. Thromb Haemost 1987;58:1073-1077
25. Conlan MG, Folsom AR, Finch A, et al. Association of factor VIII and von Willebrand factor with age, sex and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) study. Thromb Haemost 1993;70:380-385
26. Lippi G, Franchini M, Brocco G, Manzato F. Influence of the ABO blood type on the platelet function analyzer PF-100. Thromb Haemost 2001;85:369-370
27. Freyburger G, Bilhou-Nabera C, Dief S, et al. Technical and biological conditions influencing the functional APC resistance test. Thromb Haemost 1996;75:460-465
28. Favaloro EJ, Soltani S, McDonald J, Grezchnik E, Easton L. Laboratory identification of familial thrombophilia: do the pitfalls exceed the benefits? A reassessment of ABO blood group, gender, age, and other laboratory parameters on the potential influence on a diagnosis of protein C, protein S, and antithrombin deficiency and the potential high risk of a false positive diagnosis. Lab Hematol 2005;11:174-184
29. Dolan G, Neal K, Cooper P, Brown P, Preston FE. Protein C, antithrombin III and plasminogen: effect of age, sex and blood group. Br J Haematol 1994;86:798-803
30. Rodeghiero F, Tosetto A. The VITA project: population-based distributions of protein C, antithrombin III, heparin-cofactor II and plasminogen - relationship with physiological variables and establishment of reference ranger. Thromb Haemost 1996;76:226-233
31. Tait RC, Walker ID, Islam SI, et al. Protein C activity in healthy volunteers - influence of age, sex, smoking and oral contraceptives. Thromb Haemost 1993;70:281-285
32. Sakkinen PA, Cushman M, Patsy BM, et al. Correlates of antithrombin, protein C, protein S, and TFPI in a healthy elderly cohort. Thromb Haemost 1998;80:134-139
33. MacCallum PK, Cooper JA, Howarth DJ, Meade TW, Miller GJ. Sex differences in the determinants of fibrinolytic activity. Thromb Haemost 1998;79:587-590
34. Stegnar M, Pentek M. Fibrinolytic response to venous occlusion in healthy subjects: relationship to age, gender, body weight, blood lipids and insulin. Thromb Res 1993;69:81-92
35. Stegnar M, Cuderman TV, Božič M. Evaluation of preanalytical, demographic, behavioural and metabolic variables on fibrinolysis and haemostasis activation markers utilised to assess hypercoagulability. Clin Chem Lab Med 2007;45:40-46
36. Siegert G, Bergmann S, Jaross W. Relationship of PAI activity and TPA concentration with age, sex, risk factors for coronary heart disease and life style. Fibrinolysis 1994;4(Suppl 2):34-36
37. Hashimoto Y, Kobayashi A, Yamazaki N, Sugawara Y, Takada Y, Takada A. relationship between age and plasma tPA, PA-inhibitor and PA activity. Thromb Res 1987;46:625-633
38. Bowles LK, Cooper JA, Howarth DJ, et al. Associations of haemostatic variables with body mass index: a community-based study. Blood Coagul Fibrinolysis 2003;14:569-573
39. Cushman M, Lemaitre RN, Kuller LH, et al. Fibrinolytic activation markers predict myocardial infarction in the elderly. The Cardiovascular Health Study. Arterioscler Thromb Vasc Biol 1999;19:493-498
40. Haus E, Cusulos M, Sackett-Lundeen L, Swoyer J. Circadian variations in platelet functions and coagulation parameters. Ann Rev Chronopharmacol 1990;7:153-156
41. Conchonnet P, Decousus H, Boissier C, et al. Morning hypercoagulability in man. Ann Rev Chronopharmacol 1990;7:165-168
42. Toulon P, Vitoux JF, Leroy C, et al. Circulating activities during constant infusion of heparin or a low molecular weight derivative (enoxaparine): failure to demonstrate any circadian variations. Thromb Haemost 1987;58:1068-1072
43. Kluft C, Jie AFH, Rijken DC, Verheijen JH. Daytime fluctuations in blood of tissue-type plasminogen activator and its fast-acting inhibitor. Thromb Haemost 1988;59:329-332
44. Bull GM, Brozonic M, Chakrabarti R, et al. Relationship of air temperature to various chemical, haematological and haemostatic variables. J Clin Pathol 1979;32:16-20